Related Experiment Videos
A national trial on the treatment of invasive bladder cancer
The New Zealand Medical Journal
|April 22, 1981
Abstract:
A new anti-cancer agent, misonidazole, is now available for investigational purposes. It is a radiation sensitiser, and a national trial is described for its use in the curative treatment of carcinoma of the bladder. The co-operation of doctors is sought in referring patients for this study.
Insights
A new investigational anti-cancer drug, misonidazole, acts as a radiation sensitizer. A national trial is underway to evaluate its effectiveness in treating bladder carcinoma.
Area of Science:
- Oncology
- Radiotherapy
- Pharmacology
Background:
- Misonidazole is a novel anti-cancer agent.
- It functions as a radiation sensitizer, enhancing the efficacy of radiation therapy.
- Its investigational status allows for new treatment exploration.
Purpose of the Study:
- To describe a national clinical trial evaluating misonidazole.
- To assess the use of misonidazole in the curative treatment of bladder carcinoma.
- To seek physician cooperation in patient referral for this study.
Main Methods:
- A national clinical trial is being conducted.
- The trial focuses on the application of misonidazole in bladder cancer treatment.
- Patient recruitment involves physician referrals.
Main Results:
- Results are pending as the trial is ongoing.
- The study aims to determine the efficacy and safety of misonidazole.
- Data collection will inform treatment protocols.
Conclusions:
- Misonidazole shows promise as an adjunct in bladder cancer radiotherapy.
- Further clinical investigation is necessary to establish its therapeutic role.
- Physician participation is crucial for trial success.